Former President and Chief Executive Officer · Zentalis Pharmaceuticals, Inc. (ZNTL)

Anthony Sun

A named executive officer of Zentalis Pharmaceuticals in every fiscal year CompBrief holds from FY2019 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$9,098,448

Salary $245,511Stock awards $3,569,431

FY2021: $5,935,085

3rd of 7 named executive officers at Zentalis Pharmaceuticals by FY2022 total.

7 named officers on file for Zentalis Pharmaceuticals, FY2022

Anthony Sun’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • ZNTL’s disclosed peer group of 23 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Zentalis Pharmaceuticals’s whole pay program stands against its peers

  • Zentalis Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ZNTL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Anthony Sun’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anthony Sun compensation by year

Zentalis Pharmaceuticals Summary Compensation Table · all 4 fiscal years held
In US dollars, as Zentalis Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022
Salary$455,091$561,232$585,243$245,511
Bonus$0$0$0$0
Stock awards$0$8,100,645$1,695,750$3,569,431
Option awards$918,000$5,986,469$3,339,564$4,091,739
Non-equity incentive$204,971$287,375$299,808$0
Pension and deferred compensation$0$0$0$0
All other$0$108,678$14,721$1,191,767
Total$1,577,882$15,044,399$5,935,085$9,098,448

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zentalis Pharmaceuticals, Inc. DEF 14A filed April 28, 2023, accession 0001725160-23-000078, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Zentalis Pharmaceuticals, Inc. filed document, accession 0001725160-23-000078. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$1.6M
$15.0M
$5.9M
$9.1M
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU50,431$1,015,680—
RSU36,601$737,144—
RSU32,812$660,834—
Option93,670—$52.61
Option71,094—$38.76
Option166,667—$18.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Zentalis Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Zentalis Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Kimberly BlackwellChief Executive Officer$36,614,376
Cam GallagherPresident$10,629,545
Anthony Sun · this pageFormer President and Chief Executive Officer$9,098,448
Carrie BrownsteinChief Medical Officer$8,830,657
Andrea PaulGeneral Counsel and Corporate Secretary$6,214,856
Kevin BunkerChief Scientific Officer$5,722,062
Melissa EpperlyChief Financial Officer and Treasurer$4,026,248

Board service

Zentalis Pharmaceuticals board · FY2021

How this board is paid

Company policy: Zentalis Pharmaceuticals pays directors a $40,000 cash retainer. As stated in Zentalis Pharmaceuticals's FY2021 proxy.

The full Zentalis Pharmaceuticals compensation record

free company brief

This page is one person within Zentalis Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Zentalis Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zentalis Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anthony Sun's compensation dossier · One-time report. No refunds.